Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Nov 23;11(12):1407.
doi: 10.3390/pathogens11121407.

Approaching Challenges Posed by SARS-CoV-2 Genetic Variants

José de la Fuente  1   2
Affiliations
Editorial

Approaching Challenges Posed by SARS-CoV-2 Genetic Variants

José de la Fuente. Pathogens. .

Abstract

In this new collection of the most viewed and cited papers, one of the Editor's chosen articles, published in Pathogens in 2021, addressed the impact and the concerns relating to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants [...].

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Impact of SARS-CoV-2 genetic variants on individual´s protective responses to coronavirus infection and vaccination and non-protective responses associated with COVID-19 prevalence and severity.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Janik E., Niemcewicz M., Podogrocki M., Majsterek I., Bijak M. The Emerging Concern and Interest SARS-CoV-2 Variants. Pathogens. 2021;10:633. doi: 10.3390/pathogens10060633. - DOI - PMC - PubMed
    1. Dehghani J., Movafeghi A., Mathieu-Rivet E., Mati-Baouche N., Calbo S., Lerouge P., Bardor M. Microalgae as an efficient vehicle for the production and targeted delivery of therapeutic glycoproteins against SARS-CoV-2 variants. Mar. Drugs. 2022;20:657. doi: 10.3390/md20110657. - DOI - PMC - PubMed
    1. Shang W., Dai W., Yao C., Xu L., Tao X., Su H., Li J., Xie X., Xu Y., Hu M., et al. In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. Antivir. Res. 2022;208:105450. doi: 10.1016/j.antiviral.2022.105450. - DOI - PMC - PubMed
    1. Kim W.S., Kim J.H., Lee J., Ka S.Y., Chae H.D., Jung I., Jung S.T., Na J.H. Functional expression of the recombinant spike receptor binding domain of SARS-CoV-2 Omicron in the periplasm of Escherichia coli. Bioengineering. 2022;9:670. doi: 10.3390/bioengineering9110670. - DOI - PMC - PubMed
    1. Hu Q., Zhao Y., Shaabani N., Lyu X., Powers C., Sun H., Cruz V., Stegman K., Xu J., Fossier A., et al. Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta variants. Mol. Ther. Nucleic Acids. 2022;30:465–476. doi: 10.1016/j.omtn.2022.10.021. - DOI - PMC - PubMed

Publication types

LinkOut - more resources